Etaracizumab, formerly referred to as MEDI523 and subsequently LM609, represents a promising approach in anti-inflammatory therapy. This engineered protein is designed to specifically block the activity of https://mediajx.com/story28120924/etaracizumab-a-deep-review-into-medi523-and-lm609